JPM recap: Must-reads of the week, from FDA to IPO to M&A and more

Big deals, attempts at decent deals and impending IPOs—sure, the J.P. Morgan Healthcare Conference was awash in deal buzz as well as the occasional rainfall. But that's far from all the talk that came out of meeting rooms, restaurants and hotel lobbies. Here's our top coverage from FierceBiotech and FiercePharma, with a couple of extras thrown in.